CDKN2A and cancer: Hence, it is expected that utilizing deregulated E2F activity using ARF and TAp73 promoter elements provides an advantage over enhanced E2F activity in cancer cells and growth-related E2F target promoters such as E2F1, which shows high activity in normally growing cells.